Corneal Ulcer Pipeline Analysis Demonstrates Novel Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight
10 juin 2021 21h00 HE
|
DelveInsight Business Research LLP
Los Angeles, June 10, 2021 (GLOBE NEWSWIRE) -- Corneal Ulcer Pipeline Analysis Demonstrates Novel Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight The majority...
Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma Companies | DelveInsight
26 mai 2021 20h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, May 26, 2021 (GLOBE NEWSWIRE) -- Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma...
Orphan Drugs Market Global Sales Are Expected To Reach US$ 413.36 Billion by 2030, as stated by insightSLICE
02 mars 2021 09h54 HE
|
insightSLICE
PUNE, India, March 02, 2021 (GLOBE NEWSWIRE) -- The Global Orphan Drugs Market Share, Trends, Analysis and Forecasts, 2020-2030 provides insights on key developments, business strategies, research...
Orphan Drugs Market to Reach USD 340.84 Billion by 2027; Increasing Number of Regulatory Approvals will Contribute to Market Growth, says Fortune Business Insights™
21 janv. 2021 06h58 HE
|
Fortune Business Insights
Pune, Jan. 21, 2021 (GLOBE NEWSWIRE) -- The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a...
Orphan Drugs Market to Reach USD 340.84 Billion with 10.5% CAGR by 2027; Increasing Number of Regulatory Approvals will Contribute to Market Growth, says Fortune Business Insights™
26 oct. 2020 07h50 HE
|
Fortune Business Insights
Pune, Oct. 26, 2020 (GLOBE NEWSWIRE) -- The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a...
ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
11 déc. 2019 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
21 nov. 2019 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
06 nov. 2019 07h00 HE
|
ProQR Therapeutics N.V.
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020QR-1123...
ProQR to Present at Two Investor Conferences in October
30 sept. 2019 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
09 sept. 2019 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...